Skip to Content

FDA Approves Oral Treatment for Myelodysplastic Syndrome

WEDNESDAY, July 8, 2020 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) tablets, an oral outpatient treatment option for patients with myelodysplastic syndromes and chronic myelomonocytic leukemia, the agency announced Tuesday.

Inqovi provides another option for patients who previously needed intravenous therapy and will reduce the need for them to frequently visit health care facilities. The tablet is taken once daily for five consecutive days in a 28-day cycle.

The approval was based on data from the ASCERTAIN phase 3 study and supporting phase 1 and 2 clinical studies. Data showed that intravenous decitabine and Inqovi have similar drug concentrations and similar safety profiles. Also, at eight weeks, about half of the patients who had depended on transfusions no longer required transfusions.

Commonly reported side effects of Inqovi include fatigue, constipation, hemorrhage, muscle pain, mucositis, arthralgia, nausea, and fever with low white blood cell count. Inqovi can also cause fetal harm, and those of reproductive age should use effective contraception if taking Inqovi.

Approval was granted to Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceuticals.

More Information

© 2021 HealthDay. All rights reserved.

Read this next

She's Beating Leukemia With a Healthy Change to Her Diet

TUESDAY, April 6, 2021 -- Angie Gaytan never cared much for beets, but beets sure do love her -- doctors say that veggie shakes, fruits, beet juice and other healthy foods likely...

Adding in Stem Cell Therapy Helps Beat a Common Childhood Leukemia

FRIDAY, April 2, 2021 -- Combining stem cell transplants with cutting-edge immunotherapy prevents leukemia relapses in young people and improves their chances of survival, new...

Scientists Discover Why Blood Type May Matter for COVID Infection

WEDNESDAY, March 3, 2021 -- A new study provides further evidence that people with certain blood types may be more likely to contract COVID-19. Specifically, it found that the...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.